Skip to main content
SpringerLink
Log in

Celecoxib: an NSAID with improved gastrointestinal tolerability

  • New drugs and disease management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Clemett, D and Goa KL. Celecoxib. A review of its use in osteoarthritis, rheumatoid arthritis and acute pain. Drugs 2000 Apr; 59(4): 957–980

    Article  PubMed  CAS  Google Scholar 

  2. Lawrence RC, Heimick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998; 41(5): 778–99

    Article  PubMed  CAS  Google Scholar 

  3. Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol 1999; 26 Suppl. 56: 18–24

    Google Scholar 

  4. Bensen WG, Fiechtner JJ, McMillen JI, et al. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomised controlled trial. Mayo Clin Proc 1999; 74: 1095–105

    Article  PubMed  CAS  Google Scholar 

  5. Zhao SZ, McMillen JI, Markenson JA, et al. Evaluation of the functional status aspects of health-related quality of life of patients with osteoarthritis treated with celecoxib. Pharmacotherapy 1999; 19: 1269–78

    Article  PubMed  CAS  Google Scholar 

  6. Geis GS, Hubbard RC, Woods EM, et al. Efficacy of celecoxib, a COX-2 specific inhibitor, in osteoarthritis of the hip. Arthritis Rheum 1999; 42 Suppl.: 144

    Google Scholar 

  7. Simon LS, Weaver AL, Graham DY, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 1999; 282: 1921–8

    Article  PubMed  CAS  Google Scholar 

  8. Emery P, Zeidler H, Kvien TK, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet 1999; 354: 2106–11

    Article  PubMed  CAS  Google Scholar 

  9. Malmstrom K, Daniels S, Kotey P, et al. Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors in postoperative dental pain: a randomized, placebo- and active- comparator-controlled clinical trial. Clin Ther 1999; 21: 1653–63

    Article  PubMed  CAS  Google Scholar 

  10. Brugger AM, Richardson ET, Drupka DT, et al. Comparison of celecoxib, hydrocodone/acetaminophen, and placebo for relief of post-surgical pain. 18th Ann Sci Meet Am Pain Soc; 1999 Oct 21

    Google Scholar 

  11. Karim A, Piergies A, Tolbert D, et al. Selective inhibitor of cyclo-oxygenase-2 (COX-2), SC-58635 (Celecoxib), does not affect kinetics or dynamics of warfarin [abstract]. J Clin Pharmacol 1998; 38: 880

    Google Scholar 

  12. Bensen WG, Zhao SZ, Burke TA, et al. Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo. J Rheumatol 2000 Aug; 27(8): 1876–83

    PubMed  CAS  Google Scholar 

  13. British National Formulary. No. 40. London: The Pharmaceutical Press, 2000 Sep: 459-60

  14. Goldstein JL, Silverstein FE, Agrawal NM, et al. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol 2000 Jul; 95(7): 1681–90

    Article  PubMed  CAS  Google Scholar 

  15. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs non-steroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study. JAMA 13 Sep 2000; 284(10): 1247–55

    Article  CAS  Google Scholar 

  16. Whelton A, Maurath CJ, Verburg KM, et al. Renal safety and tolerability of celecoxib, a novel cyclooxygenase (COX)-2 inhibitor. Am J Ther 2000 May; 7: 159–75

    Article  PubMed  CAS  Google Scholar 

  17. Davies NM, McLachlan AJ, Day RO, et al. Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet 2000 Mar; 38(3): 225–42

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Celecoxib: an NSAID with improved gastrointestinal tolerability. Drugs Ther. Perspect 17, 1–5 (2001). https://doi.org/10.2165/00042310-200117050-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200117050-00001

Keywords

Search

Navigation